 |
|
|
|
|
Gen-Probe has a robust development pipeline of innovative nucleic acid tests (NATs). For example, the Company is developing NATs to detect prostate cancer, drug-resistant healthcare-associated infections, and the human papillomavirus, which causes cervical cancer. In addition, Gen-Probe is working with
General Electric and Millipore to develop NATs that detect microorganisms that commonly contaminate industrial processes.
For scientific publications on many of the development projects described below, go to: http://www.gen-probe.com/global/science/publications_posters.aspx.
Biopharmaceutical Manufacturing
In 2005, Millipore and Gen-Probe formed an alliance to develop, manufacture and commercialize on an exclusive basis NAT products for rapid microbiological and virus monitoring in the biotech and pharmaceutical industries. Microbiological monitoring of
manufacturing processes is critical to ensuring patient safety and meeting regulatory requirements.
For more information, go to: http://www.gen-probe.com/news/PressReleaseText.asp?compid=135117&releaseID=751341.
PROCLEIX® and ULTRIO® are trademarks of Novartis Vaccines and Diagnostics, Inc.
|
|
Gen-Probe Incorporated
10210 Genetic Center Drive
San Diego, CA 92121
USA
Map | Terms | Privacy | Help
|
|
